6. Goodwill and Indefinite-Lived Intangible Assets
|
3 Months Ended | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2015
|
||||||||||||||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||
Goodwill and Indefinite-Lived Intangible Assets |
Goodwill
A reconciliation of the change in the carrying value of goodwill is as follows:
The goodwill acquired from the Acquisition was disposed of in connection with the Hive Out Agreement. See Footnote 3, Acquisitions, for further discussion on the Acquisition and the Hive Out Agreement.
Indefinite-Lived Intangible Assets
The Companys acquired indefinite-lived intangible asset, OncoHist, is IPR&D relating to the Companys business combination with SymbioTec. As of October 1, 2014, the date of the Companys annual impairment review, the fair value of the Companys indefinite-lived intangible asset balance was $14.61 million. The carrying value of OncoHist was $9.30 million and $9.75 million as of March 31, 2015 and December 31, 2014, respectively. No impairment was recorded during the three months ended March 31, 2015 and 2014. |